Advanced search
Publication Cover
Current Medical Research and Opinion Volume 27, 2011 - Issue 6
Submit an article Journal homepage
683
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors

James SignorovitchAnalysis Group, Inc., Boston, MA, USACorrespondence[email protected]
,
Karthik RamakrishnanAnalysis Group, Inc., Boston, MA, USA
,
Rym Ben-HamadiAnalysis Group, Inc., Boston, MA, USA
,
Andrew P. YuAnalysis Group, Inc., Boston, MA, USA
,
Eric Q. WuAnalysis Group, Inc., Boston, MA, USA
,
Heather DworakForest Research Institute, Inc., Jersey City, NJ, USA
&
M. Haim ErderForest Research Institute, Inc., Jersey City, NJ, USA
 show all
Pages 1089-1096 | Accepted 25 Feb 2011, Published online: 28 Mar 2011

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Zheng-Yi Zhou, Shawn Sun, Pooja Chopra, Yichen Zhong, Todor Totev & James Signorovitch. (2015) Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Journal of Medical Economics 18:11, pages 919-929.
Read now
Daniel Souery, Raffaella Calati, Konstantinos Papageorgiou, Alzbeta Juven-Wetzler, Joël Gailledreau, David Modavi, Othman Sentissi, William Pitchot, George N. Papadimitriou, Dimitris Dikeos, Stuart Montgomery, Siegfried Kasper, Joseph Zohar, Alessandro Serretti & Julien Mendlewicz. (2015) What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. The World Journal of Biological Psychiatry 16:7, pages 472-482.
Read now

Articles from other publishers (4)

Kazuyuki Nakagome, Yuma Yokoi, Atsuo Nakagawa, Masayuki Tani, Gentaro Nishioka, Naoki Yoshimura, Toshiaki A. Furukawa, Koichiro Watanabe, Masaru Mimura, Akira Iwanami & Takayuki Abe. (2021) Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial. Journal of Affective Disorders 282, pages 1011-1020.
Crossref
Harneet Kaur, Ajeet Sidana & ThiyamKiran Singh. (2019) Comparison of efficacy and tolerability of escitalopram and venlafaxine in treatment-naïve patients with unipolar nonpsychotic depression: Is there a need to revisit the prescription patterns?. Journal of Mental Health and Human Behaviour 24:1, pages 15.
Crossref
N. Biglia, V.E. Bounous, T. Susini, S. Pecchio, L.G. Sgro, V. Tuninetti & R. Torta. (2018) Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors. European Journal of Cancer Care 27:1, pages e12484.
Crossref
P. Favré. (2012) Efficacité clinique et obtention d’une rémission complète dans la dépression : intérêt de l’escitalopram. L'Encéphale 38:1, pages 86-96.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.